Last reviewed · How we verify
Iron supplement B
Iron supplement B is a Iron supplement Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Iron deficiency anemia.
Iron supplement B replenishes iron stores to treat or prevent iron deficiency anemia by restoring hemoglobin production.
Iron supplement B replenishes iron stores to treat or prevent iron deficiency anemia by restoring hemoglobin production. Used for Iron deficiency anemia.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Iron supplement B |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Iron supplement |
| Target | Iron (Fe2+/Fe3+) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Iron is an essential component of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. By supplementing iron, this drug addresses the underlying deficiency that causes anemia, enabling the bone marrow to produce adequate red blood cells with normal oxygen-carrying capacity. The formulation or delivery mechanism specific to Iron supplement B from Tanabe Pharma may offer improved bioavailability or tolerability compared to standard iron salts.
Approved indications
- Iron deficiency anemia
Common side effects
- Gastrointestinal disturbance (nausea, constipation, abdominal discomfort)
- Dark stools
- Abdominal pain
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Comparison of Oral vs Intravenous Iron Therapy for the Treatment of Postpartum Anemia (NA)
- Effects of Iron Supplements on the Pharmacokinetics of MT-6548 (PHASE3)
- Dietary Strategy to Tackle Sarcopenia in Early Elderly Subjects (FOOP-Sarc) (NA)
- Evaluation of the Effect of FertyBiotic Pregnancy in the Metabolic Profile in Pregnant Women (NA)
- The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
- Effect of Multi Strain Probiotic on Ferritin Levels in Children with Iron Deficiency (NA)
- Aerobic Exercises on Persisted Post Burn Anemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron supplement B CI brief — competitive landscape report
- Iron supplement B updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI
Frequently asked questions about Iron supplement B
What is Iron supplement B?
How does Iron supplement B work?
What is Iron supplement B used for?
Who makes Iron supplement B?
What drug class is Iron supplement B in?
What development phase is Iron supplement B in?
What are the side effects of Iron supplement B?
What does Iron supplement B target?
Related
- Drug class: All Iron supplement drugs
- Target: All drugs targeting Iron (Fe2+/Fe3+)
- Manufacturer: Tanabe Pharma Corporation — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Iron deficiency anemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing